Datar Cancer Genetics (DCG) has launched the Target-MRD blood test, designed for the identification and monitoring of molecular residual disease (MRD) in individuals with solid organ cancers.
Hosted on MSN27d
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease MonitoringLondon [UK]/ Munich [Germany]/ New Delhi [India], January 22: Datar Cancer Genetics (DCG) today announced the launch of Target-MRD, an advanced molecular residual disease (MRD) monitoring blood ...
Thus, it is important that every Government resists the temptation to ignore these conventions for short-term gains or to settle political scores. Arvind P. Datar is a Senior Advocate.
New Delhi [India] / London [UK] / Munich [Germany], January 28: Datar Cancer Genetics (DCG) has launched a revolutionary video-reporting service for in-vitro chemosensitivity testing, powered by ...
$ 0.001 USD 0.00 0.00% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback